IL6 and hepatocellular carcinoma: Serum IL6 levels are elevated in patients with chronic hepatitis B (CHB) and HCC [8,9,10] and perform better than IL-10, IL-12 and IFNα as a biomarker of clinical progression in HBV-related chronic liver diseases [11].